Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.
Tsutomu TakeuchiKiyohiro NishikawaFumika YamadaShiro OhshimaMakoto InoueYutaka YoshiokaHisashi YamanakaPublished in: Modern rheumatology (2022)
CT-P13 showed excellent effectiveness as first-line therapy, no clinical difficulties in switching from IFX, and clinical improvement in patients who failed other bDMARDs. CT-P13 could be a cost-effective alternative to IFX in the treatment of rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis patients
- image quality
- dual energy
- rheumatoid arthritis
- computed tomography
- disease activity
- contrast enhanced
- positron emission tomography
- randomized controlled trial
- systemic lupus erythematosus
- mesenchymal stem cells
- ulcerative colitis
- ankylosing spondylitis
- combination therapy
- replacement therapy